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AbstrACt
Introduction Preventing and reducing violence against 
women (VAW) and maternal mortality are Sustainable 
Development Goals. Worldwide, the maternal mortality 
ratio has fallen about 44% in the last 25 years, and for 
one maternal death there are many women affected 
by severe acute maternal morbidity (SAMM) requiring 
management in the intensive care unit (ICU). These 
women represent the most critically ill obstetric patients 
of the maternal morbidity spectrum and should be 
studied to complement the review of maternal mortality. 
VAW has been associated with all-cause maternal 
deaths, and since many women (30%) endure violence 
usually exerted by their intimate partners and this 
abuse can be severe during pregnancy, it is important 
to determine whether it impacts SAMM. Thus, this study 
aims to investigate the impact of VAW on SAMM in the 
ICU.
Methods and analysis This will be a prospective case-
control study undertaken in a tertiary healthcare facility 
in Lima-Peru, with a sample size of 109 cases (obstetric 
patients admitted to the ICU) and 109 controls (obstetric 
patients not admitted to the ICU selected by systematic 
random sampling). Data on social determinants, medical 
and obstetric characteristics, VAW, pregnancy and neonatal 
outcome will be collected through interviews and by 
extracting information from the medical records using 
a pretested form. Main outcome will be VAW rate and 
neonatal mortality rate between cases and controls. VAW 
will be assessed by using the WHO instrument. Binary 
logistic followed by stepwise multivariate regression and 
goodness of fit test will assess any association between 
VAW and SAMM.
Ethics and dissemination Ethical approval has 
been granted by the La Trobe University, Melbourne-
Australia and the tertiary healthcare facility in Lima-
Peru. This research follows the WHO ethical and safety 
recommendations for research on VAW. Findings will be 
presented at conferences and published in peer-reviewed 
journals.
IntroduCtIon
Preventing and reducing violence against 
women and maternal mortality are sustain-
able development goals (SDGs).1 Worldwide, 
the maternal mortality ratio (MMR) has 
declined by 44% with a reduction from 385 
to 216 maternal deaths per 100 000 live births 
between 1990 (532 000 maternal deaths) and 
2015 (303 000 maternal deaths). This equates 
to approximately 830 women dying daily, of 
which 99% of maternal deaths occurred in 
developing countries.2 However, maternal 
mortality is only a small proportion of the 
global burden of the maternal morbidity 
spectrum.3–5 This is because for one maternal 
death there are many women affected by 
severe acute maternal morbidity (SAMM) 
during pregnancy, childbirth and the post-
partum period5–11 including those obstetric 
strengths and limitations of this study
 ► This prospective study will examine for the first time 
the influence of violence against women on severe 
acute maternal morbidity (SAMM).
 ► Studying the stage before maternal death (SAMM) 
complements the review of maternal mortality.
 ► This study uses a standardised global instrument 
for the evaluation of violence against women and a 
pretested form for the assessment of other variables 
of interest.
 ► Studying violence against women can be challenging 
and may underestimate the rate of abuse due to 
recall and cultural bias.
 ► Findings should be interpreted cautiously because 
this study is within one very large tertiary hospital 
and further multicentre and multicountry studies 
may be needed, based on these replicable methods.
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patients who require multidisciplinary management in 
the intensive care unit (ICU).11–17 
ICU admission can be a marker for defining SAMM,12 18–25 
and SAMM can be named as near miss; either term has 
been widely used to study this population of obstetric 
patients.15 19 21 25–28 There are no internationally accepted 
criteria for defining SAMM and its definition may differ 
across studies,19 20 25–34 and the use of ICU admission to 
identify severe maternal morbidity has high sensitivity 
(86.4%), specificity (87.8%) and positive predicted value 
(0.85).22 27 35–38 Women with SAMM treated in the ICU 
represent the most critically ill obstetric patients11 19 39 
and require timely managed care due to the physiological 
changes of pregnancy and the care of the mother–baby 
dyad.11–17 40–46
The incidence of maternal ICU admission varies from 
0.04% to 4.54%, and the common causes are mainly 
direct obstetric clinical conditions.12 14 19 29 According to 
Pollock et al,14 hypertensive disorders were the leading 
cause of ICU admission (0.09% of deliveries), followed by 
obstetric haemorrhage (0.07%) and sepsis (0.02%), and 
although the ICU admission profile was similar worldwide 
there were higher rates of maternal deaths in the ICUs of 
developing countries.
Violence against women is a global public health 
problem and many women of reproductive age endure 
violence usually exerted by their intimate partners (inti-
mate partner violence (IPV)). Globally, 30% of women 
have experienced partner abuse.47–49 However, the IPV 
rate varies across studies ranging from 15% to 71% and 
from 1% to 28% during pregnancy.50 Diverse studies have 
also reported a wide range of IPV rate during pregnancy 
from 0.9% to 20.1% in high-income countries,513% to 
44% in Latin America and Caribbean countries52 and 2% 
to 57% in African countries.53
Several studies have reported negative and mortal 
consequences of IPV on reproductive age women.54–57 
During pregnancy, these adverse health outcomes 
affect the mother–baby dyad and can be augmented by 
consequent risky health behaviours (smoking, alcohol 
consumption, substance abuse, poor nutrition, lack of 
seeking healthcare, among others)57–60 and physiolog-
ical mechanisms through neural, neuroendocrine and 
immune responses to acute and/or chronic stress orig-
inating from exposure to violence.55 61 All of this may 
exacerbate pre-existing medical conditions and/or lead 
to diverse pregnancy complications.52 55 61 62 Even though 
women could be more vulnerable to IPV during the 
pregnancy and puerperium periods, no data on violence 
against women of obstetric patients in the ICU have been 
reported in Peru or elsewhere.63 Thus, it is important to 
examine whether violence against women is a risk factor 
for women with SAMM. We are conducting this study in 
Peru, an upper middle-income country64 with a lifetime 
IPV rate of 68.2% (emotional 64.2%, physical 31.7% and 
sexual 6.6%).65 In Peru, there are about 9 cases of femi-
cide monthly56 and an MMR of 68, which fell 72.9% from 
251 between 1990 and 2015.2
There has been an increased concern about the nega-
tive influence of violence against women on maternal 
mortality,66–72 and violence against women has been asso-
ciated with all-cause maternal deaths.66 67 Although, this 
association was first analysed 16 years ago,67 there is still a 
paucity of studies investigating the influence of violence 
against women on SAMM,63 which can be considered as a 
complement to a review of maternal deaths.15 22 29 36 73–75 
Thus, it is important to determine whether violence 
against women impacts SAMM, since many women endure 
violence usually exerted by their intimate partners and 
this abuse can be severe during pregnancy. Therefore, 
this research of the stage before maternal death (SAMM) 
will provide for the first time, a better understanding 
about what potential factors, such as violence against 
women, are affecting obstetric patients with SAMM in the 
ICU. This will make an important contribution to global 
knowledge of causes of maternal morbidity.
HypotHEsIs
We hypothesise that violence against women is signifi-
cantly associated with severe acute maternal morbidity in 
obstetric patients managed in the ICU.
objECtIvEs
 ► To investigate the impact of violence against women 
on obstetric patients with SAMM treated in the ICU 
(cases) by comparing them with obstetric patients not 
admitted to the ICU (controls) in a tertiary health-
care facility in Lima,Peru;
 ► To evaluate pregnancy and neonatal outcome of 
women with SAMM in the ICU of a tertiary healthcare 
facility in Lima, Peru.
MEtHods
This is a prospective case–control study protocol and 
follows the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) criteria.76 77
study design
In this case–control study, cases will be obstetric patients 
experiencing SAMM in the ICU(s) including miscarriage, 
therapeutic abortion, unsafe abortion and ectopic preg-
nancy prospectively identified from the ICU register. The 
inclusion criteria of cases include: (1) a woman with a 
maternal ICU admission due to a complication(s) during 
pregnancy, delivery or within 42 days of the ending of preg-
nancy, with favourable evolution and who fulfils eligibility 
prior to hospital discharge; (2) 18-year-old or older; (3) 
Spanish speaker and (4) gives written informed consent. 
The exclusion criteria are: (1) a woman with mental 
illness or disabilities or other similar disabling patholo-
gies; (2) not able to provide informed consent; (3) an 
obstetric patient referred from other healthcare facilities 
for maternity care and (4) ICU stay less than 24 hours. 
The controls are from the same source population that 
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gives rise to the cases and their inclusion criteria consist 
of (1) a woman admitted to this hospital during preg-
nancy, delivery or within 42 days of the ending of preg-
nancy, with favourable evolution and who fulfils eligibility 
prior to hospital discharge; (2) 18-year-old or older; (3) 
Spanish speaker and (iv) gives written informed consent. 
The exclusion criteria are: (1) a woman with mental 
illness or disabilities or other similar disabling patholo-
gies; (2) not able to provide informed consent and (3) an 
obstetric patient referred from other healthcare facilities 
for maternity care. Favourable evolution means that an 
obstetric patient has received the required management 
for the condition responsible for her admission to the 
hospital or the ICU, is haemodynamically stable without 
requiring strict monitoring or specialised treatment, 
her life is not at risk and is well enough to be discharge 
from the hospital to home (it implies that the maternal 
morbidity has resolved for the cases).
We plan to include all cases who meet the selection 
criteria during the study period, until we reach the esti-
mated sample size of 109 obstetric patients admitted to 
the ICU. This is because there were 263 ICU admissions 
(pregnant and non-pregnant women) in 2012, 230 in 
2013 and 274 in 2014 according to the Department of 
Epidemiology of this hospital78 and, approximately 48% 
of the ICU admissions are referred from other healthcare 
facilities (as indicated by the chief of the ICU). We expect 
that cases will be recruited during a period of 12 months, 
though recruitment will continue for longer if necessary 
for the minimum sample sizes to be achieved. Controls 
will be selected by using a probability sampling method, 
specifically a systematic random sampling (without 
replacement) starting with 18 and with a value of k=131 
as the sampling interval.
setting
This study is being undertaken in a tertiary hospital 
located in the capital city of Peru (where about one-third 
of the Peruvian population live). This institution is the 
main national referral hospital for high-risk maternal and 
neonatal patients throughout Peru, where there are over 
22 000 deliveries yearly, which equates to approximately 1 
delivery every 25 min.79
sample size
The sample size will comprise 218 participants (109 
controls and 109 cases) which has been calculated by 
using the Sample Size Calculation for Unmatched Case–
Control Studies of the software open Epi80 with a 95% 
CI and a power of 80% to detect a (18.8%) difference in 
the exposure of violence against women (rate) between 
cases and controls. There are not preceding studies 
assessing the prevalence of violence against women 
among obstetric patients with SAMM in the ICU. We esti-
mated an IPV rate of 24.3% for controls and 43.1% for 
cases in accordance with previous research investigating 
the relationship between IPV and preeclampsia in Peru-
vian pregnant women at this maternity hospital.81
recruitment method
Participants will be invited to participate and recruited 
during their hospital stay once their acute medical 
condition(s) have been resolved (this will be after they 
were discharged from the ICU for the case women) and 
before they are discharged from hospital to going home. 
Women in the control group will be invited to participate 
within 1 week of a case woman being interviewed. The 
researcher (interviewer), a Spanish-speaking midwife, 
has been trained and has research experience working on 
violence against women studies and research ethics. The 
researcher will check with the hospital staff regarding eligi-
bility (selection criteria, eg, mental illness and others), 
prior to approaching and inviting potential participants 
to the study. She will also ensure that the potential partic-
ipants understand the participant information statement 
and answer all their questions and explain to the partici-
pants that they can refuse or withdraw their participation 
at any time without affecting their healthcare and rights.
data collection
Data collection commenced on 23 October 2015 
and is still ongoing. We expect to finish by the end of 
March 2018. Currently, we are collecting data from 
the medical records. Women who give consent will be 
interviewed once in private using a structured question-
naire (see online supplementary appendix 1). We will 
also extract information from their medical records 
using a pretested form developed by the team members 
(see online supplementary appendix 2).
Interview
The following information will be obtained during the 
face-to-face interview: sociodemographic characteristics 
(age, place of residence, educational level, marital status, 
occupation and type of health insurance) of the partic-
ipant and her partner; behavioural factors (smoking, 
use of alcohol or drugs); medical (previous and current 
diseases) and obstetric characteristics (number of preg-
nancies, previous abortions, prenatal care visits, previous 
caesarean sections and vaginal births; use of family plan-
ning methods; anaemia during pregnancy and use of iron 
supplements during pregnancy) and violence against 
women evaluation.
Violence against women will be assessed by using ques-
tions from a standardised instrument of the WHO.50 
These questions were validated, translated and adapted 
rigorously, since Peru was one of the countries selected 
in the WHO multicountry study instrument.50 They have 
been also used by other researchers for investigating 
violence against women in Peru, and an adapted version 
was applied in the Peruvian Demographic and Family 
Health Survey.65
Violence against women evaluation will comprise 
emotional (including controlling behaviours), phys-
ical and sexual abuse exerted by intimate partners and 
by non-intimate partners (relatives, friends or others) 
assessed 12 months before and during pregnancy. The 
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participants will answer the frequency (once or twice 
or many) for each act of emotional, physical or sexual 
violence. Violence against women will be examined in an 
empathetic, supportive and non-judgemental manner, 
giving the participants the opportunity not to answer 
any questions that make them feel uncomfortable or 
to reschedule or terminate the interview at any time. 
The interview will only be conducted with the woman 
alone and in private. If the interview is interrupted, the 
interviewer will change the topic or may terminate the 
interview correspondingly. It is expected that the inter-
view will take approximately 25–30 min. After the inter-
view, information about free social support services for 
domestic violence (available at this maternity hospital) 
will be offered to every participant including a referral 
if they wish. There will be also debriefing sessions for the 
well-being of the interviewer. Individual support/counsel-
ling can be arranged at the hospital for the interviewer or 
participant if it is needed.
Extracting data from medical records
We will extract data from the medical reports of the 
mothers and newborns (if applicable) related to SAMM, 
pregnancy outcome, fetal and neonatal characteristics 
and outcome.
SAMM data will include hospital admission date, clin-
ical causes for hospitalisation and/or ICU admission, 
diagnoses after being discharged from the ICU and/or 
the hospital, number of hospital stay days and ICU stay 
days, type of delivery, additional procedures, weeks of 
pregnancy when SAMM occurs, organ failure(s), use of 
technologies (mechanical ventilation, transfusion, use 
of inotropic support and renal replacement therapies), 
main delays (in relation to the 3 delays model frame-
work used to study maternal mortality82) and pregnancy 
outcome (see online supplementary appendix 2).
Fetal and neonatal data will include: birth weight; birth 
age; sex; Apgar score (at 1 and 5 min); outcome at birth; 
clinical cause(s) for neonatal ICU (NICU); number of 
days at the NICU (if applicable) or at the hospital; use 
of technologies and/or antibiotics at the NICU; feeding 
type (breastfeeding, formula or both); discharge status 
and diagnoses from the hospital and/or the NICU 
(see online supplementary appendix 2).
data entry and analysis
Data will be entered using SPSS V.24.0. Univariate anal-
ysis will be carried out to describe the characteristics of 
SAMM, social determinants, violence against women and 
pregnancy and neonatal outcomes. Quantitative variables 
will be displayed as the mean±SD and/or median (inter-
quartile rate) after verifying their normal or asymmet-
rical distribution. Difference of means analyses between 
variables will be performed using appropriate statistical 
tests (Student’s t-test or Mann–Whitney U test or other 
similar tests). Qualitative variables will be displayed as 
frequencies.
We will apply a bivariate analysis to evaluate the associa-
tion of violence against women (partner and non-partner) 
as an independent variable with SAMM; and we will also 
evaluate this association with partner violence only and 
with non-partner violence only.
We will fully assess violence against women as a risk 
factor by using a multivariate logistic regression model-
ling considering an OR with 95% CI. Crude ORs will also 
be calculated. Statistical significance will be set at p<0.05 
for all analyses. We will identify effect modification for 
age, level of education, alcohol consumption and use of 
drugs by performing a stratified analysis of these variables 
that could potentially modify the effect of violence against 
women on SAMM. This will be assessed by the calculation 
of crude ORs within every level of each variable that is 
stratified. The final model will include the sociodemo-
graphic characteristics of the participants, other variables 
of interest (such as household income, partner’s educa-
tional level, partner’s occupation, etc) according to the 
literature review and modifiers (we will remove the least 
significant modifiers one at a time until only those with 
p<0.05 remain). Those variables with p values of <0.25 will 
be initially chosen to be included in the model,83 and the 
Hosmer-Lemeshow’s goodness-of-fit test will be used to 
assess model adequacy and stepwise multiple regression 
analysis performed to select and identify the predictive 
factors in the final model.83
EtHICs And dIssEMInAtIon
Ethical approval has been granted by the La Trobe Univer-
sity Human Ethics committee (HEC15-023), Melbourne, 
Australia and the Institutional Review Board of the tertiary 
healthcare hospital in Lima, Peru. Individual written 
informed consent will be obtained from participants 
prior to data collection. The present research follows the 
WHO and other ethical and safety recommendations for 
research on gender-based violence to ensure the safety of 
the participants and the interviewer.50 84–88
It is planned that the findings of this case–control study 
will be presented at La Trobe University and national 
and/or international conferences, and it will be also 
published in a peer-reviewed journal. It is expected that 
these findings will inform policy-makers, patients and the 
public through these presentations.
prEsEntIng And rEportIng rEsults
This prospective case–control study will examine for 
the first time the influence of violence against women 
on obstetric patients affected by severe acute maternal 
morbidity who require management in the ICU and 
evaluate their pregnancy and neonatal outcomes. We 
will present major findings in tables and also describe 
results in narrative format outlining effect sizes and their 
parameters. The findings and further publications will 
be reported following the STROBE criteria,76 77 which is 
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part of the Enhancing the QUAlity and Transparency Of 
health Research Network website.
dIsCussIon
The influence of violence against pregnant women on 
the incidence of or type of SAMM is not known and 
worthy of study. Although, the negative contribution of 
violence against women to maternal deaths was described 
in the 1997–1999 Confidential Enquiry into Maternal 
Death,67 and many studies have reported negative and 
fatal repercussions of IPV on women’s health including 
during all stages of pregnancy,52–62 there is a paucity 
of studies assessing the relationship between violence 
against women and SAMM.63 Investigating women 
affected by SAMM could complement the review of 
maternal deaths15 22 29 36 73–75 to understand which under-
lying factors are influencing the sequence of events from 
a healthy pregnancy through minor complications to 
life-threatening obstetric conditions and even death in 
childbearing women.26 89 90
This case–control study will contribute to evidence 
about the potential negative consequences of violence 
against women of obstetric patients with SAMM in the 
ICU, who represent the most critically ill patients11 19 39 
and have been shown to be an important component 
of the maternal morbidity spectrum requiring timely 
managed care.11–17 40–46 This may help to highlight that 
non-biological factors (violence against women), which 
are potentially modifiable, may be associated with 
SAMM and are important to address to reduce maternal 
morbidity–mortality in Peru and in other low/middle-in-
come countries. Acute or chronic exposure to violence 
adversely affects both the mothers and their babies and 
can be augmented by any risky health behaviours57–60 
and through physiological (neural, neuroendocrine and 
immune) mechanisms in response to this abuse.55 61 All of 
this may exacerbate pre-existing medical conditions and/
or lead to diverse pregnancy complications.52 55 61 62 Thus, 
it would be important to know if violence against women 
is a risk factor for SAMM in the ICU and to understand 
the complete picture of the global burden of maternal 
morbidity–mortality to improve mother–baby dyad health 
and women’s well-being.
This study may also help participants affected by 
violence to disclose abuse in a safe and supportive envi-
ronment and provide an opportunity for those abused 
women to understand that it is possible to prevent 
violence and improve their and other women’s lives, since 
they will be informed and/or referred to the free social 
support services available for domestic violence provided 
by the Peruvian government.
We understand that the findings of this study should 
be interpreted cautiously and some limitations should be 
noted. First, this research will be undertaken in a single 
centre. It will be important to carry out further multi-
centre and multicountry studies. Other limitations may 
include recall, cultural and measurement bias which can 
underestimated or overestimate the exposure.50 91 This 
is because the assessment of violence against women is 
complex and challenging. Accordingly, this research 
follows the ethical and safety recommendations for 
research on violence against women50 84–88 and uses stan-
dardised questions for the assessment of violence against 
women (WHO instrument) and a pretested questionnaire 
for the evaluation of other factors. Amendments to this 
protocol are not expected. However, if any are required, 
these amendments will be reported transparently.
Notwithstanding these limitations, we hope that this 
study will contribute to the global effort towards achieving 
SDGs by providing valuable information for a better 
understanding of SAMM and violence against women in 
Peru. This will make an important contribution to global 
knowledge of causes of maternal morbidity by providing 
evidence of the relationship between violence against 
women and SAMM, which is important for preventing 
and/or reducing maternal morbidity–mortality and 
improve maternal health. Therefore, we expect that this 
research will extend knowledge in an identified research 
gap and may provide direction for further studies in 
obstetric women affected by SAMM in the ICU.
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